17β-Estradiol (E2)

Basic Information

CAS ID:	50-28-2
Molecular Formula:	C18H24O2
Molecular Weight:	272.4 g/mol
Monoisotopic Mass:	272.1776 g/mol
Class:	Small Molecule
Natural Product:	No
Other Names:	Vagifem 8 \| VIVELLE-DOT \| VIVELLE \| ESTROGEL \| ESTRADIOL HEMIHYDRATE \| ESTRADERM TTS 100 \| ESTRACE \| DIVIGEL \| DERMESTRIL SEPTEM 25 \| ADGYN ESTRO \| MENOREST 37.5 \| GVNODIOL \| FEMSEVEN 50 \| FEMPATCH \| EVOREL 25 \| EVAMIST \| DIHYDROTHEELIN \| ELESTRIN \| DIHYDROXYESTRIN \| DERMESTRIL SEPTEM 75 \| Climara Pro \| AGOFOLLIN \| Vagifem 18 \| MINIVELLE \| FEMSEVEN 75 \| ESTRADERM MX 75 \| Depo-Estradiol \| DESTRADIOL \| DERMESTRIL SEPTEM 50 \| DERMESTRIL 100 \| Aquagen \| VAGIFEM \| SANDRENA \| PROGYNOVA TS \| MENORING 50 \| FEMSEVEN 100 \| ESTRADERM MX 100 \| ESTRASORB \| ESCLIM \| E-Cypionate \| DERMESTRIL 50 \| DERMESTRIL 25 \| CLIMARA \| Alfatradiol \| MENOREST 75 \| MENOREST 50 \| Gynogen \| GYNODIOL \| FEMATRIX 40 \| EVOREL 75 \| ZUMENON \| OESTRADIOL \| FEMATRIX 80 \| ESTRADERM TTS 50 \| ESTRADERM TTS 25 \| ELLESTE SOLO MX 80 \| ELLESTE SOLO \| INNOFEM \| ESTRING \| ESTRADIOL \| ESTRADERM MX 25 \| ELLESTE SOLO MX 40 \| ELESTRIM \| BEDOL \| ALORA \| MENOSTAR \| GYNOESTRYL \| GYNERGON \| EVOREL 50 \| EVOREL 100 \| ESTRADERM MX 50 \| ESTRADERM
Analysis:	Drug repositioning mechanism analysis

Compound Structure and Identifier

InChI:	InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1	See All
InChI Key:	VOXZDWNPVJITMN-ZBRFXRBCSA-N
Smiles:	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O	See All
Molfile:	Download

Related Target

Target ID	Name	Interaction
T0538	Estrogen receptor	agonist

Related Fibrosis Property

Reference Record 1

PubMed ID	20810711	Target ID	T0538
Uniprot ID	Estrogen receptor	Name	Estrogen receptor
Model	vitro,mice	Fibrosis Disease	Cardiac fibrosis
Process I	attenue inflammation
Process II	myofibroblasts differentiation
Process III	prevenet collagen deposition
Mechanism

Trial Record 1

ClinicalTrial ID	NCT00984386	Disease	Scar
Phase	Phase 2	Status	Completed
First Received	September 25, 2009	Last Verified	September 25, 2009
Sponsor	Renovo

Trial Record 2

ClinicalTrial ID	NCT02218463	Disease	Scar
Phase	Not Applicable	Status	Unknown
First Received	August 18, 2014	Last Verified	September 12, 2014
Sponsor	Children's Mercy Hospital Kansas City

Related Link

PubChem:	5757
ChEMBL:	CHEMBL135